Overview

Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency

Status:
Completed

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

Currently, the first-line combination of artemisinin, piperaquine and prima-quine is quite effective in controlling malaria, however, the threat of spread of drug-resistant parasites has been reported. A study is conducted to assess the efficacy and safety extract of bitter melon (Momordica charantia/MC) regimens compared to the combination of dihydroartemisinin piperaquine primaquine (DHP+PQ) on the sexual and asexual stage of P. Falciparum uncomplicated in Sumba Barat Daya District, Indonesia

Phase:

Phase 2

Details

Lead Sponsor:

Syamsudin Abdillah,Ph.D, Pharm D

Treatments:

Artenimol
Piperaquine
Primaquine